Kodiak Sciences begins subject treatment in DME therapy trial

cafead

Administrator
Staff member
  • cafead   Apr 04, 2023 at 10:32: AM
via Biopharmaceutical company Kodiak Sciences has treated the first participant in the Phase I clinical trial of its investigational bispecific antibody biopolymer conjugate (ABC), KSI-501, for diabetic macular oedema (DME).

article source